HTG Molecular Diagnostics, Inc. Common Stock
HTGM
HTGM was delisted on the 14th of June, 2023.
39 hedge funds and large institutions have $32.4M invested in HTG Molecular Diagnostics, Inc. Common Stock in 2019 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 12 increasing their positions, 14 reducing their positions, and 11 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less capital invested
Capital invested by funds: $37M → $32.4M (-$4.62M)
14% less repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 14
19% less funds holding
Funds holding: 48 → 39 (-9)
73% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
+$413K |
| 2 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$389K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$200K |
| 4 |
Stifel Financial
St. Louis,
Missouri
|
+$92.4K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$75.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$2.67M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$742K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$505K |
| 4 |
RCM
Requisite Capital Management
Dallas,
Texas
|
-$254K |
| 5 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$251K |
HTGM Hedge Fund Activity: Q1 2019 in Review
39 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in HTG Molecular Diagnostics, Inc. Common Stock (HTGM) for Q1 2019, worth a combined $32.4M — down 12% from $37M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of HTGM and 3 opened new positions — a net loss of 8 holders — while 14 trimmed existing stakes and 12 added.
The largest buyer was Perkins Capital Management, adding an estimated $413K. The largest seller was Putnam Investments, exiting entirely with an estimated $2.67M sold.
- 39 institutional investors held HTG Molecular Diagnostics, Inc. Common Stock (HTGM) as of Q1 2019, down from 48 in Q4 2018.
- Funds reported $32.4M of HTG Molecular Diagnostics, Inc. Common Stock stock for Q1 2019, down 12% quarter-over-quarter.
- 3 funds opened new HTG Molecular Diagnostics, Inc. Common Stock positions in Q1 2019 and 11 closed out, a net change of -8 holders.
- The largest HTG Molecular Diagnostics, Inc. Common Stock buyer in Q1 2019 was Perkins Capital Management, an estimated $413K added.
- The largest HTG Molecular Diagnostics, Inc. Common Stock seller in Q1 2019 was Putnam Investments, an estimated $2.67M sold.
Based on aggregated 13F filings for Q1 2019.